Prolia Benefits Persist to a Decade in Postmenopausal Women

besa

https://www.medpagetoday.com/meetingcoverage/asbmr...

"The rate of nonvertebral fractures continued to decline through 10 years of treatment with denosumab (Prolia) among postmenopausal women, researchers reported here."......

"Women in the FREEDOM trial receiving subcutaneous denosumab who enrolled in the trial's long-term extension phase had a rate of nonvertebral fractures during years 1 to 3 of 1.98 (95% CI 1.67-2.34) per 100 person-years and rates of 1.54 (95% CI 1.29-1.83) per 100 patient-years during years 4 to 7, for an adjusted rate ratio of 0.79, P=0.046, according to Serge Ferrari, MD, of Geneva University Hospital in Switzerland, and colleagues.And among that group, the rate during years 4 to 10 was 1.44 (95% CI 1.24-1.66) per 100 person-years, for an adjusted RR of 0.74 (95% CI 0.60-0.93, P=0.008), Ferarri reported in a plenary session at the American Society for Bone and Mineral Research annual meeting."